Phase 1Completed
Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Simvastatin (a Sensitive CYP3A4 Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI
- Sponsor
- AstraZeneca (Industry)
- Enrollment
- 52 enrolled
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pharmacokinetic sampling - AZD9291; Simvastatin; AZD9291 tablet dosing; Pharmacokinetic sampling - simvastatin; Pharmacokinetic sampling - AZ5140 and AZ7550
- Ages
- adults, older adults
- Registry
- NCT02197234, EUCTR2014-002070-36
Full record on ClinicalTrials.gov
From the registry
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior therapy with an approved EGFR tyrosine kinase inhibitor (TKI) agent. Part A will assess the effect of AZD9291 on the pharmacokinetic (PK) parameters of simvastatin and simvastatin acid, following multiple oral dosing of AZD9291 in a fasted state. Part B will allow patients further access to AZD9291 after the PK phase (Part A) and will provide for additional safety data collection. All patients from Part A who completed treatment may continue to receive AZD9291 80 mg once daily until: disease progression; they are no longer deriving clinical benefit; or any other reason.
Primary outcomes
- Cmax of Simvastatin
- AUC of Simvastatin
History
Last registry update
Study completion
Results first posted
Primary completion
Started
Registered